Mariana Oncology specializes in the development of precision radiopharmaceuticals, which are agents designed to deliver targeted radiation to tumor sites while minimizing damage to surrounding healthy tissues. Their approach involves a sophisticated integration of target biology and ligand discovery, focusing on the design of radiopharmaceuticals that consist of a radioisotope, a targeting ligand, and a linker. The company employs both alpha and beta radionuclides, allowing for a versatile application in treating solid tumors. Mariana's ligands are engineered to enhance tumor distribution and facilitate rapid clearance from the body, which is crucial for achieving effective therapeutic profiles that surpass existing modalities.

The company’s drug development engine is tailored to the specific biology of tumor targets, utilizing a variety of ligand platforms to optimize the selection of modalities based on the characteristics of the target, such as the presence of structured extracellular domains and internalization rates. Mariana Oncology's proprietary methodologies include macrocyclic peptide-based drug discovery and innovative peptidic and non-peptidic approaches for challenging targets. Their theranostic strategy allows for the simultaneous use of diagnostic and therapeutic radionuclides, enabling precise patient selection and dose optimization during clinical development. This comprehensive approach underscores Mariana Oncology's commitment to advancing the field of precision medicine through targeted radiopharmaceuticals.

United States

Mariana Oncology is a fully integrated next generation radiopharmaceutical company that brings together experts in ligand discovery, radiochemistry, radiobiology and oncology translational and clinical research in order to build a pipeline across a range of solid tumor types. Our mission at Mariana is to discover and develop safe, effective, and highly targeted radiopharmaceuticals.

Mariana Oncology

Company Details